Atezolizumab (Tecentriq®) for adjuvant treatment of NSCLC. HTA ID: 22036

Assessment Status NCPE Assessment Process Complete
HTA ID 22036
Drug Atezolizumab
Brand Tecentriq®
Indication As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC.
Assessment Process
Rapid review commissioned 18/05/2022
Rapid review completed 02/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 04/10/2022
Full submission received from Applicant 02/12/2022
Preliminary review sent to Applicant 05/05/2023
NCPE assessment re-commenced 02/06/2023
Factual accuracy sent to Applicant 06/07/2023
NCPE assessment re-commenced 12/07/2023
NCPE assessment completed 20/07/2023
NCPE assessment outcome The NCPE recommends that atezolizumab (Tecentriq ®) should not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations, March 2024.